Quarterly ResultMay 12, 2026, 07:11 AM
C4 Therapeutics Q1 Revenue $6.2M; Net Loss $25.1M; Roche Partnership
AI Summary
C4 Therapeutics reported its first quarter 2026 financial results, with revenue decreasing to $6.2 million and net loss improving to $25.1 million. The company highlighted significant progress in its clinical pipeline, including the initiation of two new trials for cemsidomide in multiple myeloma and an expanded partnership with Roche for degrader-antibody conjugates, which included a $20 million upfront payment. C4 Therapeutics maintains a strong balance sheet with a cash runway projected to last until the end of 2028.
Key Highlights
- Q1 2026 revenue was $6.2 million, down from $7.2 million in Q1 2025.
- Q1 2026 net loss was $25.1 million, an improvement from $26.3 million in Q1 2025.
- Net loss per share for Q1 2026 was $0.20, compared to $0.37 in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $268.3 million as of March 31, 2026.
- The company expects its cash runway to extend to the end of 2028.
- Expanded partnership with Roche through a new collaboration for degrader-antibody conjugates, receiving a $20 million upfront payment.
- Initiated Phase 2 MOMENTUM trial and Phase 1b trial for cemsidomide in multiple myeloma.
- Decided not to advance CFT8919, an EGFR L858R degrader, into the next phase of clinical development outside Greater China.